Infectious, Inflammatory and Chronic Diseases
Area coordinators:
- Victoria del Pozo Abejón
VPozo@fjd.es
Consulta su CV - Raquel Largo Carazo
RLargo@fjd.es
Consulta su CV
The main characteristic of the area is the broad spectrum of pathologies studied and its multidisciplinary nature.
Its objectives include:
- To study the mechanisms of cellular and tissue damage and repair associated with certain infectious, inflammatory and chronic diseases: diseases of the respiratory system, immuno-allergy, diseases caused by infectious agents and diseases of the musculoskeletal system.
- To study the immunological and pathogenic aspects of HIV infection and viral hepatitis with the ultimate goal of contributing to the development of strategies aimed at achieving better control of these infections or their total eradication.
- To develop new methodologies of proteomic and metabolomic analysis by mass spectrometry for the identification of diagnostic and prognostic markers in different pathologies. (Translation to clinical practice).
- To study COVID-19 infection from standpoints: clinical involvement in hospitalised individuals, severity in individuals with respiratory pathologies, study of the virus and its variants, and the role of different immune cells in the infection, among others.
Infectious, Inflammatory and Chronic Disease Area Scientific Activity
|
2023 |
Allergy and Immunology |
Infectious Disease and Tropical Medicine |
Microbiology |
Pneumology |
Rheumatology and Bone Metabolism |
Traumatology |
TOTAL |
|
|
PROJECTS |
→EU/NIH PROJECTS |
// |
1 |
// |
// |
// |
// |
1 |
|
→ISCIII PROJECTS |
10 |
3 |
3 |
2 |
12 |
// |
30 |
|
|
→CYBER PROJECTS |
1 |
// |
1 |
1 |
// |
// |
3 |
|
|
→MINISTERIAL PROJECTS |
1 |
// |
// |
1 |
// |
// |
2 |
|
|
→ACM PROJECTS |
6 |
// |
1 |
// |
1 |
// |
8 |
|
|
→AWARDS |
// |
// |
// |
// |
// |
// |
// |
|
|
→UNOFFICIAL PROJECTS |
14 |
10 |
2 |
11 |
13 |
2 |
52 |
|
|
→OBSERVATIONAL STUDIES |
7 |
6 |
// |
2 |
1 |
2 |
18 |
|
|
TOTAL |
39 |
20 |
7 |
17 |
27 |
4 |
114 |
|
|
CLINICAL TRIALS |
→EARLY PHASES (I, I/II, II) |
3 |
6 |
// |
1 |
2 |
// |
12 |
|
→LATE PHASES (II/III, III, III/IV AND IV/OTHER) |
4 |
14 |
// |
11 |
4 |
15 |
48 |
|
|
TOTAL |
7 |
20 |
// |
12 |
6 |
15 |
60 |
Infectious, Inflammatory and Chronic Disease Area Publications
|
2023 |
Total no. of publications |
No. of publications with IF |
Accumulated IF |
Average annual IF |
No. of journals in Q1 |
% of journals in Q1 |
No. of publications in Open Access |
No. of Clinical Practice Guidelines |
|
Allergy and Immunology |
52 |
50 |
378,2 |
7,56 |
40 |
80,00% |
40 |
7 |
|
Infectious Disease and Tropical Medicine |
33 |
28 |
236,1 |
8,43 |
11 |
39,29% |
21 |
1 |
|
Microbiology |
34 |
33 |
227,2 |
6,88 |
17 |
51,52% |
27 |
0 |
|
Pneumology |
35 |
24 |
233 |
9,71 |
17 |
70,83% |
32 |
4 |
|
Rheumatology and Bone Metabolism |
60 |
60 |
375,7 |
6,26 |
26 |
43,33% |
43 |
3 |
|
Traumatology |
50 |
36 |
95,4 |
2,65 |
7 |
19,44% |
31 |
3 |
|
INFECTIOUS, INFLAMMATORY AND CHRONIC DISEASES AREA |
264 |
231 |
1545,6 |
6,69 |
118 |
51,08% |
194 |
18 |
List of the five most relevant publications of the Infectious, Inflammatory and Chronic Disease Area during 2023
European Respiratory Society short guidelines for the use of as-needed ICS/formoterol in mild asthma.
Papi A, Ferreira DS, Agache I, Baraldi E, Beasley R, Brusselle G, Coleman C, Gaga M, Gotera Rivera CM, Melén E, Pavord ID, Peñate Gómez D, Schuermans D, Spanevello A, Tonia T, Schleich F.
Eur Respir J. 2023 Oct.62(4).
PMID: 37678955
FI: 24,9
Uncovering therapeutic opportunities in the clinical development of antibody-drug conjugates.
Nieto-Jiménez C, Sanvicente A, Díaz-Tejeiro C, Moreno V, Lopez de Sá A, Calvo E, Martínez-López J, Pérez-Segura P, Ocaña A.
Clin Transl Med. 2023 Sep.13(9):e1329.
PMID: 37740463
FI: 10,6
Long-term immune response accompanies clinical outcomes in severe asthmatics treated with anti-IL-5/IL-5R biologics.
Lorente-Sorolla C, Bernaola J, Sánchez-Mellado D, Gil-Martínez M, Naharro-González S, Betancor D, Fernández-Nieto M, Pinillos-Robles EJ, Santillán Coello JM, Villacampa-Aubá JM, Rodríguez-Nieto MJ, Sastre J, Valverde-Monge M, Rodrigo-Muñoz JM, Del Pozo V.
Allergy. 2023 Aug 29.
PMID: 37643083
FI: 12,4
MSC therapy ameliorates experimental gouty arthritis hinting an early COX-2 induction.
Medina JP, Bermejo-Álvarez I, Pérez-Baos S, Yáñez R, Fernández-García M, García-Olmo D, Mediero A, Herrero-Beaumont G, Largo R.
Front Immunol. 2023.14:1193179.
PMID: 37533852
FI: 7,3
Microbiome-derived cobalamin and succinyl-CoA as biomarkers for improved screening of anal cancer.
Serrano-Villar S, Tincati C, Raju SC, Sáenz JS, Moreno E, Bargiela R, Cabello-Ubeda A, Sendagorta E, Kurz A, Perez Molina JA, de Benito A, Hov JR, Fernandez-Lopez L, Muriel A, Del Campo R, Moreno S, Trøseid M, Seifert J, Ferrer M.
Nat Med. 2023 Jul.29(7):1738-1749.
PMID: 37464040
FI: 82,9
Gender perspective in the Infectious, Inflammatory and Chronic Disease Area
The Infectious, Inflammatory and Chronic Disease area is made up of a group of professionals committed to respect and equality among its team members, which seeks to promote the professional development of all its personnel without discrimination based on gender or age.
Infectious, Inflammatory and Chronic Disease Area Future Goals
- Identification of molecular bases, diagnostic biomarkers, evolution and new therapeutic targets in inflammatory diseases by applying proteomics, metabolomics and genomics, especially in anaphylaxis, asthma and respiratory diseases.
- HIV infection studies: disease progression, functional cure models and search for potential therapeutic targets, identifying the impact of the coexistence of two viruses (HIV and HCV) on the host immune system.
- Bacterial infections and infections associated with biomaterials: new lines of diagnosis and treatment (phage and nanoparticle-based therapies), and development of new vaccines, as well as infection models.
- Synovial biopsy study in chronic arthritis: search for tissue markers of prognosis and/or response to treatment. Application of musculoskeletal ultrasound as a prognostic marker in psoriatic arthritis. Study of the participation of the purinergic system and energy management in musculoskeletal diseases, and their possible therapeutic repercussions.
- Clinical studies on the treatment of prevalent fractures associated with osteoporosis and anatomical and embryological studies on the anatomy of the shoulder applied to surgery.
- Application of telemedicine and technology to support hospitals in low-income areas.
- Innovation in big data, diagnosis and treatment of infectious, inflammatory and chronic diseases.
Research groups
- Allergy and Immunology Group
- Infectious Disease and Tropical Medicine Group
- Microbiology Group
- Pneumology Group
- Rheumatology and Bone Metabolism Group
- Traumatology Associated Group
